Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Expanded Access to VAL-083

Next Previous
X
Search
Trial Profile

Expanded Access to VAL-083

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 24 Nov 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dianhydrogalactitol (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Sponsors DelMar Pharmaceuticals; Kintara Therapeutics

    • Most Recent Events

    • 20 Nov 2023 Status changed from recruiting to completed.
    • 19 Apr 2023 Results assessing the efficacy and safety (As of cut-off date 05 Jan, 2023) of VAL-083 in patients with recurrent glioblastoma, presented at the 114th Annual Meeting of the American Association for Cancer Research.
    • 15 Mar 2023 According to a Kintara Therapeutics Media Release, results of this study will be presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting, taking place in Orlando, April 14-19.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top